National Institute of Allergy and Infectious Diseases (NIAID)

FLC Region

Security Lab

No

Address

Technology Transfer and Intellectual Property Office
5601 Fishers Lane
Bethesda, MD 20892-9804
United States

Laboratory Representative

Description

The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 50 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world.

Tech Areas

Available Technologies
Displaying 81 - 90 of 190
Human Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) cDNA
Human Neutralizing Monoclonal Antibodies to Respiratory Syncytial Virus and Human Neutralizing Antibodies to Respiratory Syncytial Virus
Hybridoma C4H3, Monoclonal Antibody to a Specific Peptide-MHC Class II Complex
Hybridoma Cell Line 25-D1.16 Producing Monoclonal Anti-H-2Kb/SIINFEKL Complex Antibody
Hybridoma Cell Line 273 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp70
Hybridoma Cell Line 3C7 Producing Monoclonal Anti-mouse CD25 (IL-2 receptor, alpha chain) Antibody
Hybridoma Cell Line 500 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp80
Hybridoma Cell Line 715 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp70
Hybridoma Cell Line 7D4 Producing Monoclonal Anti-mouse CD25 (IL-2 receptor) Antibody
Hybridoma Cell Line B6GE1, Monoclonal Antibody to the Specific Peptide-MHC Class II Complex

Pages

Funding

New Direct-to-SBIR Phase II Funding Award for NIAID Intramural Diagnostic Inventions

The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), is pleased to announce the first NIAID Small Business Innovation Research-Technology Transfer (SBIR-TT) Direct-to-Phase II awards to move commercially viable diagnostic technologiesfrom NIAID intramural research laboratories into the marketplace. Direct-to-Phase II awards of up to $2M allow small businesses to compete even if they did not receive a Phase I SBIR award for research in the same area. An SBIR Phase II research and development plan tests the viability of the technology scientifically as well as its potential for commercialization. This Funding Opportunity Announcement (FOA)offers 18 diagnostic inventions for further development by small businesses. The list includes technologies related to hepatitis, cancer, tropical diseases, as well as other areas. As the lead federal organization conducting and supporting scientific research on infectious and immunologic diseases, NIAID carries out basic, applied, and clinicalinvestigations within intramurallaboratories and provides extramural grant, cooperative agreement, and contractsupport to research scientists worldwide. Any project that fits within the NIAID mission and relies on the use of the NIAID'u s intramural technologieslisted is eligible for this award.

Please contact Dr. Haiqing Li to discuss NIAID inventions. See FOA: NIAID SBIR - Technology Transfer Direct Phase II (SBIR-TT) (R44) for the details on eligibility and applying, or see the FAQ page for additional information.

No Programs for this lab
Facilities
Displaying 1 - 3 of 3
NIAID Core Facilities (Various)
Office of Chief Scientist, Integrated Research Facility (OCSIRF)
Rocky Mountain Laboratories (RML)
No Equipment for this lab
No publications for this lab
No awards for this lab
No news for this lab
Submit an Article
No success stories for this lab
Submit an Success Story